Released Nov 10, 2025, after the close
10-Q filed Nov 10, 2025, 41 days after period end · 0001628280-25-051031
Q3 2025 · 10-Q
Revenue—
Net Income-$12.75M-$12.75M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.32-$0.32 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$13,264,534N/M
Operating Cash Flowderived-$13,364,375N/M
Free Cash Flowderived-$13,364,375N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$12.75M | -$3.90M | -$24.95M | -$3.13M |
| EPS Diluted | -$0.32 | -$0.10 | -$3.17 | -$1.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR